Thyroid cancer: towards a new standard treatment

In a low-risk thyroid cancer, four therapeutic strategies by iodine-131 after surgical resection of the gland are also effective, according to a study conducted by a team of the Institute Gustave Roussy. But one of these approaches is distinguished from others by a better tolerance and less irradiation of the body. It should therefore become the new standard for treatment as such.

A new standard treatment for thyroid cancer. To set the therapeutic strategy the most effective in the treatment of low thyroid cancer risk, after complete surgery of the thyroid, the Pr Martin Schlumberger (Chief of nuclear medicine at the Institute de cancerologie Gustave Roussy, Villejuif) and 24 French centers colleagues compared the 4 existing approaches 752 patients divided into four groups.

Thyroid cancer

The patients were treated by:

-withdrawal in thyroid hormone, and then 100 mill curies of iodine 131 (which corresponds to the standard treatment);

-thyroid hormone withdrawal, then 30 mill curies of iodine 131;

-thyroid hormone therapy, injections of human TSH recombinant then 100 mill curies of iodine 131;

-thyroid hormone therapy, injections of human TSH recombinant then 30 mill curies of iodine 131.

It is clear that the four approaches have equivalent efficacy in terms of destruction of thyroid tissue remaining, more than 90%, indicate the rig in a press release.

Nevertheless, the approach which is to administer thyroid hormone to compensate for the lack of thyroid and then inject the TSH recombinant human before administering radioactive iodine avoids hypothyroidism due to thyroid hormone withdrawal, specify the authors. Moreover, the administration of a dose of 30 mill curies Front list as effective as that of 100 mill curies, this approach is less radiation to the body.

The authors of the study, published in the New England Journal of Medicine, must soon lead new work using this new standard as new therapeutic approach for the treatment of patients with thyroid cancer at low risk.